Literature DB >> 17329558

Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody.

Cornelis K van der Ent1, Hans Hoekstra, Ger T Rijkers.   

Abstract

Allergic bronchopulmonary aspergillosis (ABPA) can cause severe worsening of the respiratory condition in patients with cystic fibrosis. Treatment can result in steroid dependency and serious adverse events. A dramatic and rapid improvement of respiratory symptoms and lung function after a single dose of anti-IgE antibody (omalizumab) in a 12-year-old girl with cystic fibrosis and ABPA is described. This is the first report of this experimental treatment. It suggests an important role for IgE in the pathogenesis of ABPA and offers new therapeutic possibilities.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17329558      PMCID： PMC2117163          DOI： 10.1136/thx.2004.035519

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


  5 in total

Review 1.  Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference.

Authors:  David A Stevens; Richard B Moss; Viswanath P Kurup; Alan P Knutsen; Paul Greenberger; Marc A Judson; David W Denning; Reto Crameri; Alan S Brody; Michael Light; Marianne Skov; William Maish; Gianni Mastella
Journal:  Clin Infect Dis       Date:  2003-10-01       Impact factor: 9.079

2.  Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma.

Authors:  Guenther Hochhaus; Laurence Brookman; Howard Fox; Charles Johnson; John Matthews; Song Ren; Yamo Deniz
Journal:  Curr Med Res Opin       Date:  2003       Impact factor: 2.580

3.  Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.

Authors:  S T Holgate; A G Chuchalin; J Hébert; J Lötvall; G B Persson; K F Chung; J Bousquet; H A Kerstjens; H Fox; J Thirlwell; G Della Cioppa
Journal:  Clin Exp Allergy       Date:  2004-04       Impact factor: 5.018

4.  Specific serum immunopatterns in clinical phases of allergic bronchopulmonary aspergillosis.

Authors:  C Leser; H F Kauffman; C Virchow; G Menz
Journal:  J Allergy Clin Immunol       Date:  1992-10       Impact factor: 10.793

5.  Development of immune responses to Aspergillus at an early age in children with cystic fibrosis.

Authors:  J M el-Dahr; R Fink; R Selden; L K Arruda; T A Platts-Mills; P W Heymann
Journal:  Am J Respir Crit Care Med       Date:  1994-12       Impact factor: 21.405
  5 in total
  31 in total

Review 1.  Fungal Pathogens in CF Airways: Leave or Treat?

Authors:  A Singh; A Ralhan; C Schwarz; D Hartl; A Hector
Journal:  Mycopathologia       Date:  2017-08-02       Impact factor: 2.574

2.  Life-threatening allergic bronchopulomnary aspergillosis treated with methylprednisolone and anti-IgE monoclonal antibody.

Authors:  Matthew F Thomas
Journal:  J R Soc Med       Date:  2009-07       Impact factor: 5.344

Review 3.  Off-Label Uses of Omalizumab.

Authors:  David El-Qutob
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

Review 4.  Severe asthma with fungal sensitization.

Authors:  Ritesh Agarwal
Journal:  Curr Allergy Asthma Rep       Date:  2011-10       Impact factor: 4.806

5.  [Pulmonary allergic reactions].

Authors:  A R Koczulla; B Beutel; T Greulich; A Jerrentrup; C Vogelmeier
Journal:  Internist (Berl)       Date:  2012-08       Impact factor: 0.743

Review 6.  Refractory asthma - An old disorder: Novel approaches for effective control.

Authors:  B N B M Prasad
Journal:  Med J Armed Forces India       Date:  2016-06-24

Review 7.  Allergic bronchopulmonary aspergillosis.

Authors:  Paul A Greenberger; Robert K Bush; Jeffrey G Demain; Amber Luong; Raymond G Slavin; Alan P Knutsen
Journal:  J Allergy Clin Immunol Pract       Date:  2014-11-06

8.  Omalizumab for exacerbations of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.

Authors:  Patrick Lebecque; A Leonard; M Argaz; Véronique Godding; Charles Pilette
Journal:  BMJ Case Rep       Date:  2009-03-05

Review 9.  Omalizumab: Anti-IgE therapy in allergy.

Authors:  Matthias Volkmar Kopp
Journal:  Curr Allergy Asthma Rep       Date:  2011-04       Impact factor: 4.806

Review 10.  Eosinophilic pneumonias.

Authors:  Praveen Akuthota; Peter F Weller
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.